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Abstract
In a previous study we obtained and characterized in vitro a novel pseudorabies virus (PRV) variant named gIp2 with a TK,
gI/gE, 11k and 28k negative phenotype and a duplication of PK gene. The main objective of the present study was to deter-
mine the safety and efficacy, as a vaccine candidate, of this recombinant PRV. For this purpose, we used 24 PRV seronegati-
ve three weeks old piglets that were divided into five groups of treatment. Piglets of groups A and B were immunized twice
with 106.5 and 105.5 TCID50 of gIp2, respectively; pigs of group C were vaccinated twice with MLV vaccine Auskipra GN®
and pigs of groups D and E were not immunized and served as infected and uninfected controls, respectively. Four weeks after
the second immunization pigs of groups A, B, C and D were challenged by intranasal inoculation of 106 TCID50 of the wild-
type NIA-3 strain of PRV. No adverse reactions or clinical signs were observed in any group after immunization, indicating
that the application of up to 10 times the conventional dose included in a commercial vaccine (i.e. 105.5 TCID50) of gIp2 was
safe in piglets. Additionally, the inoculation of gIp2 induced an immune response able to provide clinical and virological pro-
tection against pseudorabies virus after challenge. In conclusion, the use of gIp2 in piglets as a vaccine virus is safe and indu-
ces an immunity comparable to that exerted by commercially available vaccines. 
Additional key words: immunization, protection, safety, vaccine.
Resumen
Caracterización biológica de un virus de la enfermedad de Aujeszky recombinante
En un estudio anterior, nuestro grupo de investigación había obtenido y caracterizado in vitro una nueva variante del
virus de la enfermedad de Aujeszky (PRV) denominado gIp2, que presenta un fenotipo TK, gI/gE, 11K y 28K negativo,
así como una duplicidad en el gen que codifica la PK. El principal objetivo de este estudio fue determinar la seguridad y
eficacia, como candidato vacunal, de este virus recombinante. Para ello utilizamos 24 lechones de tres semanas de vida
seronegativos al PRV, que fueron divididos en cinco grupos distintos. Los lechones de los grupos A y B fueron inmuniza-
dos dos veces con  106.5 y 105.5 DI50CT del virus gIp2; los lechones del grupo C fueron inmunizados dos veces con la vacu-
na comercial Auskipra GN® y, finalmente, los lechones de los grupos D y E permanecieron sin inmunizar y se utilizaron
como testigos infectados y sin infectar, respectivamente. Cuatro semanas después de la segunda inmunización los lecho-
nes de los grupos A, B, C y D fueron desafiados por vía intranasal con 106 DI50CT de la cepa virulenta NIA-3. Tras la
inmunización no se observaron reacciones adversas ni signos clínicos en ninguno de los grupos, indicando que la aplica-
ción de hasta 10 veces la dosis convencional de una vacuna comercial (i.e.105.5 DI50CT) del virus gIp2 es segura en lecho-
nes. Además, la inoculación del virus gIp2 indujo una respuesta inmune capaz de estimular una protección clínica y viro-
lógica tras el desafío. En resumen, la utilización del virus gIp2 como virus vacunal en lechones es segura e induce una
inmunidad comparable a la producida por vacunas comerciales.
Palabras clave adicionales: inmunización, protección, seguridad, vacunas.
Abbreviations used: ADG (average daily gain); ANOVA (analysis of variance); CPE (cytopathic effect); DMEM (Dulbecco’s modified
Eagle medium); dpc (days post-challenge); ELISA (enzyme-linked immunosorbent assay); FBS (foetal bovine serum); FCE (food con-
version efficiency); gE, gI and gG (glycoproteins E, I and G, respectively); MLV (modified-live virus); NIA-3 (Northern Ireland
Aujeszky-3 strain of PRV); PK (protein-kinase); PK-15 (porcine kidney 15); PRV (pseudorabies virus); SN (seroneutralization assay);
TCID50 (tissue culture infective dose 50); TK (timidin-kinase).
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Introduction
Pseudorabies is one of the most relevant pig diseases
that affect swine industry. The causative agent is a line-
ar double-stranded DNA virus, pseudorabies virus
(PRV), which has spread worldwide causing huge eco-
nomical losses. The most remarkable signs of PRV
infection are severe, and usually lethal, nervous disor-
ders in young piglets, fever, depression, respiratory and
nervous symptoms in weaned and fattening pigs, and
reproductive failure and nervous signs in adults. 
Several modified live virus (MLV) vaccines against
PRV have been developed by attenuation on cell cultu-
res, chemical or thermal treatment and by genetic engi-
neering techniques. In the last years, the improvement
achieved on molecular biology and genetic engineer has
permitted to increase the knowledge about the involve-
ment of PRV proteins in virulence and attenuation. The
role of timidin-kinase (TK) and the glycoprotein E (gE)
proteins in PRV attenuation has been widely studied. gE
is a membrane protein, non-essential for virus replica-
tion and involved in PRV dissemination through epithe-
lial cells in the primary replication site, respiratory tract
and in neuronal synapses. Therefore, the lack of expres-
sion of gE protein has been shown to attenuate the PRV
by reduction of the virulence and neuronal colonization.
Nonetheless, it does not reduce the level of immunolo-
gical stimulation, that seems to be similar to the patho-
genic Northern Ireland Aujeszky-3 (NIA-3) strain of
PRV. Moreover, the application of gE- vaccines reduce
field strain latency after challenge. On the other hand,
TK protein has an essential role for viral replication,
being indispensable for infective virion production in
non-dividing cells such as neurons and blood mononu-
clear cells. Consequently, the deletion of the gene
coding for TK protein results in a significant reduction
of the virulence and neuronal colonization. Recent stu-
dies have shown that deletion of genes coding for gE
and TK proteins could have a synergic effect on PRV
attenuation. 
Studies carried out by Fernández et al. (1999) des-
cribed the development and in vitro characterization of
a novel PRV variant named gIp2, produced by genetic
recombination between two PRV isomers. During the
recombination process a part of the US component was
deleted resulting in a TK, gI/gE, 11k and 28k negative
phenotype. The level of replication of gIp2 has been
evaluated in vitro, showing half of the replication
capacity of the wild strain NIA-3 in Vero cell line,
derived from monkey kidney, and 35 times lower than
NIA-3 and similar to the vaccine strain Bartha in SH-
SY5Y cells, derived from human neuroblastoma.
Moreover, a duplication of protein-kinase (PK) gene
was produced during the recombination process. The
effect of this diploidy on pathogenesis is still un -
known. However, the PK protein seems to be involved
in blockade of apoptosis in infected cells and its inac-
tivation leads to a reduction of the level of in vitro
replication, that could be related to the reduction of the
protective immune-properties. Consequently, the
diploidy of US3-encoded PK gene could play an
important role in the development of an appropriate
immune response against PRV infection.
The main objective of the present study was the cha-
racterization of the biological function of the recombi-
nant PRV gIp2, in order to determine its safety and effi-
cacy as a vaccine candidate and as a viral vector for
heterologous protein expression. An additional objecti-
ve was to determine the possible influence of the PK
protein duplication on the immune-protective properties
of gIp2 against PRV infection.
Material and methods
Virus and cell culture
Experiments were performed using the recombinant
PRV gIp2, which has been propagated onto porcine kid-
ney (PK-15) cell line, using Dulbecco´s modified
Eagle´s medium (DMEM) supplemented with antibio-
tics and 5% foetal bovine serum (FBS). Infectivity titers
were determined in PK-15 cell cultures and adjusted
with DMEM to 106.5 and 105.5 tissue culture infectious
doses 50 (TCID50) mL-1.
The pseudorabies MLV vaccine Auskipra GN®
(Laboratorios Hipra, Spain), which is derived from Bar-
tha K-61 strain of PRV, was used following the manu-
facturer’s instructions.
Challenge was performed using the virulent NIA-3
strain of PRV. Growth was carried out onto PK-15 cul-
tures using DMEM supplemented with antibiotics and
5% FBS. Infectivity titers were determined in PK-15
cultures and adjusted with DMEM to 106 TCID50 mL-1.
Animals and facilities
Twenty-four 3-week-old crossbred (Landrace x Large
White) pigs with no detectable PRV serum antibody
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titers measured by ELISA test (HerdChek PRV gB,
IDEXX Laboratories, Spain) were included in this expe-
riment. The pigs were randomly divided into five
groups, assigned to one treatment group and housed in
isolated pens with a concrete floor and automatic wate-
ring system.
Experimental design and sample collection
The study comprised five experimental groups. Five
pigs, members of group A (numbered 1, 2, 3, 4, 5), and
five pigs of group B (numbered 6, 7, 8, 9, 10) were
immunized twice on days 0 and 21 with 106.5 and 105.5
TCID50 of gIp2, respectively. Five pigs from group C
(numbered 11, 12, 13, 14, 15) were vaccinated twice, on
days 0 and 21, with MLV vaccine Auskipra GN® follo-
wing manufacturer’s instructions. Five pigs from group
D (numbered 16, 17, 18, 19, 20) and four pigs from
group E (numbered 21, 22, 23, 24) were not immunized
and served as infected and uninfected controls, respec-
tively. 
Four weeks after the second immunization (day + 0)
pigs from groups A, B, C and D were challenged by
intranasal inoculation of 106 TCID50 of the wild-type
NIA-3 strain of PRV. 
All pigs were examined daily for clinical signs and
rectal temperatures were measured. The clinical signs
observed were classified as non-specific signs, respi-
ratory signs, cutaneous signs and nervous signs. Non-
specific signs were evaluated using the following sco-
ring system: depression received a score of 1 when
present, anorexia a score of 2 and letargia a score of 3;
for the respiratory signs, sneezing was scored 1, coug-
hing and nasal secretions were scored 2, superficial
breathing was scored 3 and abdominal breathing was
scored 4; for cutaneous signs, cyanosis was scored 1;
finally, nervous signs were evaluated following this
scoring system: shivering was scored 1, nistagmous
was scored 2, incoordination was scored 3, opistoto-
nous and paddling were scored 4 and paralysis was
scored 5. Additionally, food intake, average daily gain
(ADG) and food conversion efficiency (FCE) index
were recorded.
Blood samples were collected in serum-clot vacuum
tubes on each vaccination day and then 3, 6, 9, 14 and
21 days post-vaccination, at challenge and 3, 6, 9 and 16
days post-challenge (dpc). Serum was obtained from all
blood samples and stored at -80ºC until its utilization
for virus isolation and serological assays.
Dry cotton-tipped nasal swabs were used to collect
nasal exudates on the same day of each blood collection.
Swabs were immersed in 2 mL of DMEM and stored at
-80ºC until they were used for virus isolation.
Sixteen days after challenge (D+16) all pigs were
euthanized and tissue samples were collected, including
lung, tonsils, thymus, ileum, brain, adrenal gland, and
submandibular, superficial inguinal, mediastinic and
mesenteric lymph nodes. All these tissues were stored at
-80ºC until they were processed for virus isolation.
Virus isolation and virus titration
The aliquots of sera were thawed at room temperatu-
re, diluted 1:4 in DMEM and passed through a filter
with 0.45 µm pores. Nasal swabs immersed in DMEM
were thawed at room temperature, homogenized and
passed through a filter with 0.45 µm pores. We homo-
genized 1 g of each tissue sample with 9 mL of DMEM,
centrifuged at 1200 g for 20 min at 4ºC and the super-
natant was passed through a filter with 0.45 µm pores. 
All samples were added in duplicate (200 µL well-1)
onto PK-15 cell monolayers seeded in 24-well plates
and incubated for 90 min at 37ºC to facilitate adsorp-
tion. The cultures were washed twice with DMEM and
fresh DMEM containing 5% FBS was added. The cultu-
re plates were incubated at 37ºC in a humidified atmos-
phere containing 5% CO2. Monolayers were examined
for cytopathic effect (CPE) on days 4, 5 and 6 post-ino-
culation.
We used DMEM as the diluent for virus titration.
Serial 10-fold dilutions of experimental PRV and posi-
tive clinical samples were made in 96-well microtiter
plates previously seeded in PK-15 cultures. The cell
cultures were incubated at 37ºC, in a humidified
atmosphere of 5% CO2 in air. Monolayers were exami-
ned for CPE on days 4, 5 and 6 post-inoculation. The
number of positive wells per dilution was recorded.
Titers were calculated as previously described and
were expressed as TCID50 mL-1 for fluid samples or
TCID50 g-1 for tissue samples, after adjusting for the
dilutions made when preparing the samples for virus
isolation.
Serological examinations
Serum samples were examined for PRV-specific anti-
bodies using the ELISA kit HerdChek PRV gB (IDEXX
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Laboratories, Spain) and gE protein antibodies using the
ELISA kit INGEZIM ADVgI® (Ingenasa, Spain). 
Seroneutralization assay (SN) was performed onto
PK-15 cell cultures. Sera were two-fold diluted, using
DMEM as diluent, in 96-well tissue culture plates and
200 TCID50 of NIA-3 strain of PRV were added to each
well. The culture plates were incubated for 1 hour at
37ºC in a humidified atmosphere containing 5% CO2.
After that time, 100 µL of a suspension containing 2 x
105 PK-15 cells mL-1 were added to each well. The pla-
tes were then incubated at 37ºC in a humidified atmos-
phere containing 5% CO2 and were examined for CPE
on days 4, 5 and 6 post-inoculation.
Statistical analysis
Analysis of variance (ANOVA) and Duncan´s multi-
ple range test were used to compare clinical scores,
body weight, ADG, PRV titers and neutralizing antibo-
dies among the different groups. T-student was used to
analyze differences on rectal temperature before and
after each immunization and challenge. Statistical
analysis was performed using SPSS software package
and results were considered statistically significant
when p < 0.05.
Results
Clinical examinations
Experimental immunization did not produce any cli-
nical sign or side effect. However, clinical signs associa-
ted to PRV infection were detected in animals from
groups A, B, C and D after challenge. These clinical
manifestations were more intense in pigs of group D
and included letargia, severe respiratory disorders, cya-
nosis, hyper-salivation and other neurological signs, as
incoordination and paddling. The clinical signs were so
severe that led to death of 100% of the animals, three of
them on day +3 (i.e. 3 dpc) and the other two on day +5
(i.e. 5 dpc). Less severe clinical signs were observed
after challenge in pigs of groups A, B, and C. Nonethe-
less, systemic and respiratory signs were observed in all
groups. Particularly, depression or letargia were obser-
ved in most animals of group A between days +2 and +4
and in most animals of groups B and C between days +2
and +5. Later on, systemic signs were observed in two,
one and one pigs of group B on days +6, +7 and +8, res-
pectively and in two and three pigs of group C on days
+7 and +8, respectively. Additionally, mild respiratory
signs were observed in some pigs of groups A and B
from day +1 to day +5 and in some pigs of group C from
day +1 to day +9. All these signs tended to be milder in
groups A and B compared to group C, to the point that
the differences in mean values of clinical signs were sta-
tistically significant on day +1 (i.e. 1 dpc) for groups A
and B (p=0.003), on day +5 (i.e. 5 dpc) for group A
(p=0.002) and on day +7 (i.e. 7 dpc) for groups A and B
(p=0.011). Moreover, a significant reduction in clinical
sign duration was observed in groups A and B in com-
parison to group C (p<0.001). 
Rectal temperatures measured after immunization
showed a slight increase in comparison to pre-immuni-
zation data only on day 1 (i.e. 1 day after first immu-
nization) in groups A (p=0.014), B (p=0.031) and C
(p=0.040), though a maximum value of 39.7ºC was
only recorded in one or two animals per group. After
challenge, significant increases in rectal temperature
were recorded on day +1 (i.e. 1 dpc) in group B
(p=0.014) and on days +2, +3 and +4 (i.e. 2, 3 and 4
dpc) in group A (p<0.001; p=0.004; p=0.015, respecti-
vely), B (p<0.001; p=0.001; p<0.001), C (p<0.001;
p=0.003; p=0.003) and D (p<0.001; p=0.030;
p=0.010) (Figure 1).
All uninfected-control pigs remained in normal
health status throughout the experiment.
Productive performance
None of the immunization protocols produced any
negative repercussions on productive parameters (body
weight, ADG, food intake and FCE). After challenge,
the death of all pigs from group D on days +3 and +5
(i.e. 3 and 5 dpc) made impossible to compare pre-
viously immunized (groups A, B and C) and non-immu-
nized-challenged (group D) groups. Although a detri-
ment in food intake, which was lower in group A, and a
statistically significant reduction on ADG were obser-
ved in groups A, B and C in comparison to group E
(p=0.001), the body weight measured and the FCE cal-
culated after challenge were similar among all groups. 
Virus isolation
PRV was not isolated from any serum sample collec-
ted throughout the experimental period.
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Virus isolation was achieved from nasal swabs taken
from all the animals from groups A, B and C on day 3
(i.e. 3 days after first immunization), from one pig from
group C on day 9 (i.e. 9 days after first immunization)
and from one pig from group A and one from group B
on day 24 (i.e. 3 days after second immunization) (Table
1). After challenge, PRV was isolated on day +3 (i.e. 3
dpc) from all the nasal swabs collected from pigs of
groups A, B, C and D and on days +9 and +16 (i.e. 9 and
16 dpc) from two and one pigs belonging to group C,
respectively. However, there were not statistically signi-
ficant differences in PRV titer detected in nasal secre-
tions between groups (Table 1).
PRV was not detected in any tissue sample collected
from groups A, B, C and E. PRV was isolated from pigs
belonging to group D from lung, brain, adrenal gland,
tonsils, ileum and submandibular, mesenteric, mediasti-
nic and inguinal lymph nodes (Table 2).
Serology
ELISA results showed that all immunized animals
(groups A, B and C) had seroconverted on day 21 (i.e.
21 days after first immunization). Due to the death of all
the animals from group D between days +3 and +5 (i.e.
3 and 5 dpc), we could only collect two serum samples
after challenge, on day +3, that were negative by ELISA
test. Animals from group E remained seronegative until
the end of the experiment.
Antibodies against PRV gE protein were not detected
before challenge. After challenge four out of five ani-
mals from groups A, B and C had seroconverted by day
+16 (i.e. 16 dpc). Due to the death of all the animals
from group D, it was only possible to analyze serum
samples taken from two pigs on day +3 (i.e. 3 dpc), that
were negative for antibodies against gE.
Twenty-one days after the first immunization, pigs
from groups A, B and C had serum neutralizing antibo-
dies titers ranging from 1 to 4 log2. Previous to challen-
ge exposure, the titer of neutralizing antibodies reached
by pigs of group A was significantly higher than that
attained by the pigs of the rest of the groups. At chal -
lenge, mean neutralizing antibody titers of pigs from
groups A, B and C were 6, 4.57 and 4.04 log2, respec-
tively (Figure 2). After PRV infection, antibody titers
achieved by pigs from groups B and C were signifi-
cantly higher than those of group A, reaching at the end
of the experiment mean values of 9.59, 9.56 and 8 log2,
respectively (Figure 2).
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Figure 1. Average rectal temperature measured after challenge with NIA-3 strain of PRV. The sign “#” expresses statistically sig-
nificant differences between groups (p<0.05).
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Day of the experiment
1st immunization 2nd immunization ChallengeGroup Animal
D.0 D.3 D.6 D.9 D.14 D.21 D.24 D.27 D.30 D.35 D.42 D+0 D+3 D+6 D+9 D+16
1 - + - - - - - - - - - - + (3) - - -
2 - + - - - - - - - - - - + (4.8) - - -
3 - + - - - - + - - - - - + (3.6) - - -
4 - + - - - - - - - - - - + (4.3) - - -
A
5 - + - - - - - - - - - - + (3.3) - - -
6 - + - - - - - - - - - - + (4.2) - - -
7 - + - - - - - - - - - - + (4) - - -
8 - + - - - - + - - - - - + (6) - - -
9 - - - - - - - - - - ND - + (6.3) - - -
B
10 - + - - - - - - - - - - + (4.5) - - -
11 - + - + - - - - - - - - + (4.3) - + (< 2) -
12 - + - - - - - - - - - - + (4.5) - + (< 2) -
13 - + - - - - - - - - - - ND - - + (< 2)
14 - + - - - - - - - - - - + (4.5) - - -
C
15 - + - - - - - - - - - - + (4.5) - - -
16 - - - - - - - - - - - - + (3.8) ND ND ND
17 - - - - - - - - - - - - ND ND ND ND
18 - - - - - - - - - - - - ND ND ND ND
19 - - - - - - - - - - - - ND ND ND ND
D
20 - - - - - - - - - - - - + (5.5) ND ND ND
21 - - - - - - - - - - - - - - - -
22 - - - - - - - - - - - - - - - -
23 - - - - - - - - - - - - - - - -
E
24 - - - - - - - - - - - - - - - -
Table 1. PRV isolation from nasal swabs collected pre- and post- challenge
In parenthesis: viral titer expressed as log10 TCID50 mL-1; ND: non-determined
Discussion
This study assessed the safety of the recombinant
PRV gIp2 and its ability to induce protection against the
highly virulent NIA-3 strain of PRV, under experimental
conditions. 
In the safety experiment, we included two groups of
pigs exposed by the intramuscular route to different
doses of gIp2, one of them 10 times higher than mean
doses normally used in commercial vaccines, and a
positive control, consisting in a group of pigs that were
vaccinated with a commercial MLV vaccine (Auskipra
GN®). The immunization of the pigs did not cause
remarkable adverse reactions in any of the groups and
only transient increases in body temperature, similar to
those reported by other authors after inoculation of
piglets with other PRV MLV vaccines, were recorded in
some animals of groups A and C. 
The absence of clinical manifestations, productivity
detriment and viremia after immunization, as well as the
shedding pattern in nasal swabs, similar between gIp2
and the MLV vaccine Auskipra GN®, allows us to con-
clude that our recombinant PRV gIp2 is, at least, as safe
as other PRV vaccine strains. This bio-safety is probably
related to the deletion of the genes coding for gE and
TK proteins in gIp2. In this sense, it has been proven
that gE protein is involved in PRV dissemination
through epithelial cells in the primary replication site
and the respiratory tract and the complex gI/gE in the
trans-synaptic spread of the virus. Consequently, the eli-
mination of the gI/gE complex expression leads to a
reduction in virulence and neuro-invasiveness. On the
other hand, the absence of the TK protein has been rela-
ted to attenuation because it is essential to produce
infectious viral particles in non-dividing cells, such as
neurons or blood mononuclear cells. 
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In parenthesis: viral titer expressed as log10 TCID50 g-1; ND: non-determined; a:submandibular lymph node. b:mesenteric lymph. c:mediastinic
lymph node. d:superficial inguinal lymph node.
Group Animal Lung Brain Adrenal Tonsils Ileon Thymus a Sub Ln bMes Ln c Med Ln dIng Ln
1 - - - - - - - - - -
2 - - - - - - - - - -
3 - - - - - - - - - -
4 - - - - - - - - - -
A
5 - - - - - - - - - -
6 - - - - - - - - - -
7 - - - - - - - - - -
8 - - - - - - - - - -
9 - - - - - - - - - -
B
10 - - - - - - - - - -
11 - - - - - - - - - -
12 - - - - - - - - - -
13 - - - - - - - - - -
14 - - - - - - - - - -
C
15 - - - - - - - - - -
16 + (2.5) - - +  (4.6) - ND +  (4.5) - +  (3.5) +  (<2)
17 +   (<2) - ND +  (4) - ND +  (3.6) - +  (2.6) -
18 +   (<2) - - +  (6.1) - ND +  (4.5) - - -
19 +   (<2) - - +  (3.6) +  (2.5) ND +  (2.2) - +    (2) -
D
20 +  (4.5) +  (2.6) +  (3) +  (4.5) - ND +  (3.5) - +    (3) +  (3.3)
21 - - - - - - - - - -
22 - - - - - - - - - -
23 - - - - - - - - - -
E
24 - - - - - - - - - -
Table 2. PRV isolation from tissue samples collected at necropsy
The second objective of our study was to evaluate
the immune-protective properties of the recombinant
PRV gIp2. For this purpose, we exposed the immuni-
zed piglets to 106 TCID50 of the highly virulent PRV
strain NIA-3. The results obtained indicate that the cli-
nical and virological protection conferred by gIp2 is
equal to that elicited by the commercial vaccine Auski-
pra GN®, or even higher when the dose of gIp2 to
which the pigs are exposed is high (i.e. 106.5 TCID50).
In terms of clinical manifestations, our results point
out that all immunogens used in our study are able to
confer some degree of protection. In this sense,
although hypertermia, lasting 4 or 5 days, was obser-
ved after challenge in pigs of all immunized groups,
this finding is consistent with previous reports that
have described hypertermia for 4-5 days in vaccinated
pigs, in contrast to hypertermia of up to 10 days in no-
immunized pigs. Additionally, although systemic and
respiratory signs were found in pigs of all challenged
groups, the signs observed were milder in immunized
groups than in the non-immunized group, in which all
animals died as a consequence of exposure to wild-
type PRV NIA-3. These results are also similar to
those obtained by other authors who observed the pre-
sence of mild clinical signs between days 2 and 7 after
challenge of vaccinated pigs. Moreover, clinical pro-
tection seems to be dependent on the amount of anti-
gen to which the animals are exposed. In this sense, the
group of pigs exposed to a higher dose of gIp2 showed
a significant reduction in the severity and a significant
shortening in the duration of clinical manifestations
compared to the rest of immunized pigs.
The virological protection provided by gIp2 was
determined by PRV detection in serum and peripheral
tissues. PRV was never detected in any serum sample
of any of the experimental groups. In the same way,
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no virus was isolated from any tissue sample of any of
the previously immunized pigs, which is in agreement
with previous reports of viral distribution in vaccina-
ted animals. However, PRV was detected in several
tissue samples of non-immunized-challenged con-
trols, especially in lung, tonsils and different lymph
nodes, as has been previously described after challen-
ge of non-immunized animals. The colonization of tis-
sues in the absence of viremia in this group could be
explained by the ability of PRV to spread from the pri-
mary replication site associated to leucocytes, lymph
and throughout neurons. Specifically, PRV can access
to endothelial cells from blood monocytes by fusion
of plasmatic membrane in the process of tissue colo-
nization. 
In addition, we studied the immune response elici-
ted by vaccination. Generally speaking, our recombi-
nant PRV induces an immune response similar to that
generated by the commercial vaccine used in our expe-
riment or that reported by others after immunization
with gE-, TK- or gI-/gE-/TK- strains or PRV. However,
it is remarkable that the group of pigs exposed to a hig-
her dose of gIp2, i.e. group A, experienced a marked
increase in the titer of neutralizing antibodies after the
second immunization, to the point that a significantly
higher mean titer of neutralizing antibodies was obser-
ved in this group at the time of challenge, compared to
the other two immunized groups. On the contrary, the
titer of neutralizing antibodies increased only modera-
tely in this group after challenge while an abrupt incre-
ase was observed in pigs from groups B and C. The
different patterns observed in the development of neu-
tralizing antibodies could be related to protection.
Although we do not know the reasons for the differen-
ces observed, our hypothesis is that the higher antigen
mass to which pigs of group A were exposed for
immunization might have induced a higher titer of
neutralizing antibodies before challenge. Then, the
high titer of neutralizing antibodies present at challen-
ge might have caused a more efficient blockage of
PRV infection, which would have led to a significant
reduction in the viral replication in the primary repli-
cation sites and a reduction in the amount of antigen
present in the host, which, in turn, might have caused
a lower stimulation of the immune system and might
explain the moderate increase of neutralizing antibo-
dies observed after challenge. 
Finally, it was expected that antibodies against gE
protein of PRV could not be detected before challenge
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Figure 2. Geometric mean of the titer of neutralizing antibodies against PRV expressed as log2. Neutralizing antibody titers lower
than 2 are considered negative. The sign “#” expresses statistically significant differences between groups (p<0.05).
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bility of gIp2 as a MLV candidate because it allows to
discriminate between vaccinated and infected animals.
However, gE seroconversion after challenge was expec-
ted because the pigs were exposed to a tremendous
amount of virulent PRV to demonstrate the efficacy of
the tested vaccines. 
In summary, the results of our study shows that
immunization of 3-week old piglets with the recombi-
nant PRV gIp2 is safe and induces a immunity capable
of conferring protection against PRV infection similar
to that conferred by commercially available MLV vac-
cines. Moreover, a better protection is achieved when a
higher dose of gIp2 is used in the immunization proto-
col, probably because of a stronger stimulation of the
immune system that induces higher titers of neutrali-
zing antibodies at challenge, which are capable of pro-
tecting more effectively against pseudorabies infec-
tion.
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